Rapamycin exerts antifungal activity in vitro and in vivo against mucor circinelloides via FKBP12-dependent inhibition of tor

Eukaryotic Cell

Volumn 11, Issue 3, 2012, Pages 270-281

  Bastidas, Robert J ^a   Shertz, Cecelia A ^a   Lee, Soo Chan ^a   Heitman, Joseph ^a   Cardenas, Maria E ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; FK 506 BINDING PROTEIN; FUNGAL PROTEIN; IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN; TACROLIMUS; TARGET OF RAPAMYCIN KINASE;

ANIMAL; ANTIFUNGAL RESISTANCE; ARTICLE; DRUG ANTAGONISM; DRUG EFFECT; GENETIC COMPLEMENTATION; GENETIC TRANSFECTION; GENETICS; HUMAN; LARVA; METABOLISM; MICROBIOLOGY; MOTH; MUCOR; MUTATION; PHYLOGENY; PROTEIN BINDING; SACCHAROMYCES CEREVISIAE; TWO HYBRID SYSTEM;

ANIMALS; ANTIFUNGAL AGENTS; DRUG RESISTANCE, FUNGAL; FUNGAL PROTEINS; GENETIC COMPLEMENTATION TEST; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LARVA; MOTHS; MUCOR; MUTATION; PHYLOGENY; PROTEIN BINDING; SACCHAROMYCES CEREVISIAE; SIROLIMUS; TACROLIMUS; TACROLIMUS BINDING PROTEIN 1A; TOR SERINE-THREONINE KINASES; TRANSFECTION; TWO-HYBRID SYSTEM TECHNIQUES;

GALLERIA MELLONELLA; MUCOR; MUCOR CIRCINELLOIDES; SACCHAROMYCES CEREVISIAE;

EID: 84863234110     PISSN: 15359778     EISSN: None     Source Type: Journal    
DOI: 10.1128/EC.05284-11     Document Type: Article

References (61)

1. Baker H, Sidorowicz A, Sehgal SN, Vezina C. 1978. Rapamycin (AY-22,989), a new antifungal antibiotic. III. In vitro and in vivo evaluation. J. Antibiot. (Tokyo) 31:539-545.
2. Barquilla A, Crespo JL, Navarro M. 2008. Rapamycin inhibits trypanosome cell growth by preventing TOR complex 2 formation. Proc. Natl. Acad. Sci. U. S. A. 105:14579-14584.
3. Bastidas RJ, Reedy JL, Morales-Johansson H, Heitman J, Cardenas ME. 2008. Signaling cascades as drug targets in model and pathogenic fungi. Curr. Opin. Invest. Drugs 9:856-864.
4. Beck T, Hall MN. 1999. The TOR signalling pathway controls nuclear localization of nutrient-regulated transcription factors. Nature 402:689-692.
5. Cafferkey R, et al. 1993. Dominant missense mutations in a novel yeast protein related to mammalian phosphatidylinositol 3-kinase and VPS34 abrogate rapamycin cytotoxicity. Mol. Cell. Biol. 13:6012-6023.
6. Cardenas ME, Cutler NS, Lorenz MC, Di Como CJ, Heitman J. 1999. The TOR signaling cascade regulates gene expression in response to nutrients. Genes Dev. 13:3271-3279.
7. Cardenas ME, Heitman J. 1995. FKBP12-rapamycin target TOR2 is a vacuolar protein with an associated phosphatidylinositol-4 kinase activity. EMBO J. 14:5892-5907.
8. Cardenas ME, et al. 1994. Immunophilins interact with calcineurin in the absence of exogenous immunosuppressive ligands. EMBO J. 13:5944-5957.
9. Chamilos G, Lionakis MS, Lewis RE, Kontoyiannis DP. 2007. Role of mini-host models in the study of medically important fungi. Lancet Infect. Dis. 7:42-55.
10. Cherkasova VA, Hinnebusch AG. 2003. Translational control by TOR and TAP42 through dephosphorylation of eIF2alpha kinase GCN2. Genes Dev. 17:859-872.
11. Choi J, Chen J, Schreiber SL, Clardy J. 1996. Structure of the FKBP12- rapamycin complex interacting with the binding domain of human FRAP. Science 273:239-242
12. CLSI. 2002. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard. CLSI document M38-A. CLSI, Wayne, PA.
13. Cowen LE, et al. 2009. Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease. Proc. Natl. Acad. Sci. U. S. A. 106:2818-2823.
14. Cruz MC, et al. 1999. Rapamycin antifungal action is mediated via conserved complexes with FKBP12 andTORkinase homologs in Cryptococcus neoformans. Mol. Cell. Biol. 19:4101-4112.
15. Cruz MC, et al. 2000. Immunosuppressive and nonimmunosuppressive cyclosporine analogs are toxic to the opportunistic fungal pathogen Cryptococcus neoformans via cyclophilin-dependent inhibition of calcineurin. Antimicrob. Agents Chemother. 44:143-149.
16. Cruz MC, et al. 2001. Rapamycin and less immunosuppressive analogs are toxic to Candida albicans and Cryptococcus neoformans via FKBP12- dependent inhibition of TOR. Antimicrob. Agents Chemother. 45:3162-3170.
17. Dannaoui E, Schwarz P, Lortholary O. 2009. In vitro interactions between antifungals and immunosuppressive drugs against zygomycetes. Antimicrob. Agents Chemother. 53:3549-3551.
18. Ferrara A, Cafferkey R, Livi GP. 1992. Cloning and sequence analysis of a rapamycin-binding protein-encoding gene (RBP1) from Candida albicans. Gene 113:125-127.
19. Fox DS, et al. 2001. Calcineurin regulatory subunit is essential for virulence and mediates interactions with FKBP12-FK506 in Cryptococcus neoformans. Mol. Microbiol. 39:835-849.
20. Futer O, DeCenzo MT, Aldape RA, Livingston DJ. 1995. FK506 binding protein mutational analysis. Defining the surface residue contributions to stability of the calcineurin co-complex. J. Biol. Chem. 270:18935-18940.
21. Galat A. 2000. Sequence diversification of the FK506-binding proteins in several different genomes. Eur. J. Biochem. 267:4945-4959.
22. Griffith JP, et al. 1995. X-ray structure of calcineurin inhibited by the immunophilin-immunosuppressant FKBP12-FK506 complex. Cell 82: 507-522.
23. Hardwick JS, Kuruvilla FG, Tong JK, Shamji AF, Schreiber SL. 1999. Rapamycin-modulated transcription defines the subset of nutrientsensitive signaling pathways directly controlled by the Tor proteins. Proc. Natl. Acad. Sci. U. S. A. 96:14866-14870.
24. Heitman J, Movva NR, Hall MN. 1991. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 253:905-909.
25. Hemenway CS, et al. 1995. vph6 mutants of Saccharomyces cerevisiae require calcineurin for growth and are defective in vacuolar H(-)-ATPase assembly. Genetics 141:833-844.
26. Hemenway CS, Heitman J. 1996. Immunosuppressant target protein FKBP12 is required for P-glycoprotein function in yeast. J. Biol. Chem. 271:18527-18534.
27. High KP, Washburn RG. 1997. Invasive aspergillosis in mice immunosuppressed with cyclosporin A, tacrolimus (FK506), or sirolimus (rapamycin). J. Infect. Dis. 175:222-225.
28. Hur S, Bruice TC. 2002. The mechanism of cis-trans isomerization of prolyl peptides by cyclophilin. J. Am. Chem. Soc. 124:7303-7313.
29. Katinka MD, et al. 2001. Genome sequence and gene compaction of the eukaryote parasite Encephalitozoon cuniculi. Nature 414:450-453.
30. Kubota H, Obata T, Ota K, Sasaki T, Ito T. 2003. Rapamycin-induced translational derepression of GCN4 mRNA involves a novel mechanism for activation of the eIF2 alpha kinase GCN2. J. Biol. Chem. 278:20457-20460.
31. Labbe S, Thiele DJ. 1999. Copper ion inducible and repressible promoter systems in yeast. Methods Enzymol. 306:145-153.
32. Li CH, et al. 2011. Sporangiospore size dimorphism is linked to virulence of Mucor circinelloides. PLoS Pathog. 7:e1002086.
33. Liu J, et al. 1991. Calcineurin is a common target of cyclophilincyclosporin A and FKBP-FK506 complexes. Cell 66:807-815.
34. Loewith R, et al. 2002. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol. Cell 10: 457-468.
35. Lorenz MC, Heitman J. 1995. TOR mutations confer rapamycin resistance by preventing interaction with FKBP12-rapamycin. J. Biol. Chem. 270:27531-27537.
36. Martel RR, Klicius J, Galet S. 1977. Inhibition of the immune response by rapamycin, a new antifungal antibiotic. Can. J. Physiol. Pharmacol. 55: 48-51.
37. Nicolas FE, de Haro JP, Torres-Martinez S, Ruiz-Vazquez RM. 2007. Mutants defective in a Mucor circinelloides dicer-like gene are not compromised in siRNA silencing but display developmental defects. Fungal Genet. Biol. 44:504-516.
38. Nicolas FE, Torres-Martinez S, Ruiz-Vazquez RM. 2003. Two classes of small antisense RNAs in fungal RNA silencing triggered by nonintegrative transgenes. EMBO J. 22:3983-3991.
39. Odom A, Del Poeta M, Perfect J, Heitman J. 1997. The immunosuppressant FK506 and its nonimmunosuppressive analog L-685,818 are toxic to Cryptococcus neoformans by inhibition of a common target protein. Antimicrob. Agents Chemother. 41:156-161.
40. Odom A, et al. 1997. Calcineurin is required for virulence of Cryptococcus neoformans. EMBO J. 16:2576-2589.
41. Pemberton TJ. 2006. Identification and comparative analysis of sixteen fungal peptidyl-prolyl cis/trans isomerase repertoires. BMC Genomics 7:244.
42. Powers T, Walter P. 1999. Regulation of ribosome biogenesis by the rapamycin-sensitive TOR-signaling pathway in Saccharomyces cerevisiae. Mol. Biol. Cell 10:987-1000.
43. Rees JR, Pinner RW, Hajjeh RA, Brandt ME, Reingold AL. 1998. The epidemiological features of invasive mycotic infections in the San Francisco Bay area, 1992-1993: results of population-based laboratory active surveillance. Clin. Infect. Dis. 27:1138-1147.
44. Roden MM, et al. 2005. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin. Infect. Dis. 41:634-653.
45. Rogers TR. 2008. Treatment of zygomycosis: current and new options. J. Antimicrob. Chemother. 61(Suppl 1):i35-i40.
46. Rohde JR, Bastidas R, Puria R, Cardenas ME. 2008. Nutritional control via Tor signaling in Saccharomyces cerevisiae. Curr. Opin. Microbiol. 11: 153-160.
47. Rusnak F, Mertz P. 2000. Calcineurin: form and function. Physiol. Rev. 80:1483-1521.
48. Shertz CA, Bastidas RJ, Li W, Heitman J, Cardenas ME. 2010. Conservation, duplication, and loss of the Tor signaling pathway in the fungal kingdom. BMC Genomics 11:510.
49. Singh N, et al. 2009. Zygomycosis in solid organ transplant recipients: a prospective, matched case-control study to assess risks for disease and outcome. J. Infect. Dis. 200:1002-1011.
50. Singh N, et al. 2007. Cryptococcus neoformans in organ transplant recipients: impact of calcineurin-inhibitor agents on mortality. J. Infect. Dis. 195:756-764.
51. Spellberg B, Edwards J, Jr, Ibrahim A. 2005. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin. Microbiol. Rev. 18:556-569.
52. Spellberg B, Ibrahim AS. 2010. Recent advances in the treatment of mucormycosis. Curr. Infect. Dis. Rep. 12:423-429.
53. Stan R, et al. 1994. Interaction between FKBP12-rapamycin and TOR involves a conserved serine residue. J. Biol. Chem. 269:32027-32030.
54. Sun HY, Singh N. 2011. Mucormycosis: its contemporary face and management strategies. Lancet Infect. Dis. 11:301-311.
55. Vakil R, Knilans K, Andes D, Kwon GS. 2008. Combination antifungal therapy involving amphotericin B, rapamycin and 5-fluorocytosine using PEG-phospholipid micelles. Pharm. Res. 25:2056-2064.
56. van Heeswijck R, Roncero MIG. 1984. High frequency transformation of Mucor with recombinant plasmid DNA. Carlsberg Res. Commun. 49:597-609.
57. Vezina C, Kudelski A, Sehgal SN. 1975. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J. Antibiot. (Tokyo) 28:721-726.
58. Wedaman KP, et al. 2003. Tor kinases are in distinct membraneassociated protein complexes in Saccharomyces cerevisiae. Mol. Biol. Cell 14:1204-1220.
59. Wong GK, Griffith S, Kojima I, Demain AL. 1998. Antifungal activities of rapamycin and its derivatives, prolylrapamycin, 32-desmethylrapamycin, and 32-desmethoxyrapamycin. J. Antibiot. (Tokyo) 51:487-491.
60. Zheng XF, Florentino D, Chen J, Crabtree GR, Schreiber SL. 1995. TOR kinase domains are required for two distinct functions, only one of which is inhibited by rapamycin. Cell 82:121-130.
61. Zinzalla V, Sturgill TW, Hall MN. 2010. TOR complexes: composition, structure, and phosphorylation, p 1-20. In Michael NH, Fuyuhiko T (ed), The enzymes, vol 27. Academic Press, San Diego, CA.